Trametinib is an IEC inhibitor drug with anticancer activity. MEK1 and MEK2 inhibitors. Trametinib has shown good results in phase III clinical trials in metastatic melanoma with BRAF V600E mutation.
| API&Intermediates | CAS | Structural formula | Drug | Minimum order quantity | |
|---|---|---|---|---|---|
| 1 | N-3，3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-di | 871700-24-2 |
|
Intermediate | 5g |
| 2 | 3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methylamino)pyrim | 871700-22-0 |
|
Intermediate | 5g |
| 3 | Trametinib | 871700-17-3 |
|
API | 5g |
